Cargando…

TRAIL-R2 Superoligomerization Induced by Human Monoclonal Agonistic Antibody KMTR2

The fully human monoclonal antibody KMTR2 acts as a strong direct agonist for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor 2 (TRAIL-R2), which is capable of inducing apoptotic cell death without cross-linking. To investigate the mechanism of direct agonistic activity indu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tamada, Taro, Shinmi, Daisuke, Ikeda, Masahiro, Yonezawa, Yasushi, Kataoka, Shiro, Kuroki, Ryota, Mori, Eiji, Motoki, Kazuhiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4682084/ https://www.ncbi.nlm.nih.gov/pubmed/26672965 http://dx.doi.org/10.1038/srep17936

Ejemplares similares

Structural characteristics of alkaline phosphatase from the moderately halophilic bacterium Halomonas sp. 593
por: Arai, Shigeki, et al.
Publicado: (2014)

Mutagenesis of the crystal contact of acidic fibroblast growth factor
por: Honjo, Eijiro, et al.
Publicado: (2008)

Creation of Cross-Linked Crystals With Intermolecular Disulfide Bonds Connecting Symmetry-Related Molecules Allows Retention of Tertiary Structure in Different Solvent Conditions
por: Hiromoto, Takeshi, et al.
Publicado: (2022)

Structure of a highly acidic β-lactamase from the moderate halophile Chromohalobacter sp. 560 and the discovery of a Cs(+)-selective binding site
por: Arai, Shigeki, et al.
Publicado: (2015)

Low-Level Endothelial TRAIL-Receptor Expression Obstructs the CNS-Delivery of Angiopep-2 Functionalised TRAIL-Receptor Agonists for the Treatment of Glioblastoma
por: Krishna Moorthy, Nivetha, et al.
Publicado: (2021)

Crystal structure of UDP-glucose:anthocyanidin 3-O-glucosyltransferase from Clitoria ternatea
por: Hiromoto, Takeshi, et al.
Publicado: (2013)

Neutron structure of the T26H mutant of T4 phage lysozyme provides insight into the catalytic activity of the mutant enzyme and how it differs from that of wild type
por: Hiromoto, Takeshi, et al.
Publicado: (2017)

Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists
por: Urso, Loredana, et al.
Publicado: (2017)

Sorafenib Sensitizes Solid Tumors to Apo2L/TRAIL and Apo2L/TRAIL Receptor Agonist Antibodies by the Jak2-Stat3-Mcl1 Axis
por: Abdulghani, Junaid, et al.
Publicado: (2013)

Dacarbazine and the Agonistic TRAIL Receptor-2 Antibody Lexatumumab Induce Synergistic Anticancer Effects in Melanoma
por: Engesæter, Birgit, et al.
Publicado: (2012)

Involvement of p38 Activation and Mitochondria in Death of Human Leukemia Cells Induced by an Agonistic Human Monoclonal Antibody Fab Specific to TRAIL Receptor 1
por: Lee, You-Ri, et al.
Publicado: (2019)

Relationship between the agonist activity of synthetic ligands of TRAIL-R2 and their cell surface binding modes
por: Chekkat, Neila, et al.
Publicado: (2018)

Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists
por: Grinkevitch, Vera, et al.
Publicado: (2022)

Molecular Mode of Action of TRAIL Receptor Agonists—Common Principles and Their Translational Exploitation
por: Wajant, Harald
Publicado: (2019)

Structural basis of LaDR5, a novel agonistic anti-death receptor 5 (DR5) monoclonal antibody, to inhibit DR5/TRAIL complex formation
por: Qiao, Chunxia, et al.
Publicado: (2012)

TRAIL-R1 and TRAIL-R2 Mediate TRAIL-Dependent Apoptosis in Activated Primary Human B Lymphocytes
por: Staniek, Julian, et al.
Publicado: (2019)

Identification of Novel Epitopes with Agonistic Activity for the Development of Tumor Immunotherapy Targeting TRAIL-R1
por: Guo, Lu, et al.
Publicado: (2017)

Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells
por: Trivedi, Rachana, et al.
Publicado: (2015)

Targeting Death Receptor TRAIL-R2 by Chalcones for TRAIL-Induced Apoptosis in Cancer Cells
por: Szliszka, Ewelina, et al.
Publicado: (2012)

TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells
por: Tuthill, Mark H, et al.
Publicado: (2014)

TRAIL-receptor preferences in pancreatic cancer cells revisited: Both TRAIL-R1 and TRAIL-R2 have a licence to kill
por: Mohr, Andrea, et al.
Publicado: (2015)

Following the trail from COX-2 to clotting
por: Bashyam, Hema
Publicado: (2007)

hvTRA, a novel TRAIL receptor agonist, induces apoptosis and sustained growth retardation in melanoma
por: Fleten, Karianne G, et al.
Publicado: (2016)

The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells
por: Legler, Karen, et al.
Publicado: (2018)

Marizomib sensitizes primary glioma cells to apoptosis induced by a latest-generation TRAIL receptor agonist
por: Boccellato, Chiara, et al.
Publicado: (2021)

Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody
por: Martini, Silvia, et al.
Publicado: (2020)

Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin
por: Belyanskaya, Larisa L, et al.
Publicado: (2007)

TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic
por: Ralff, Marie D., et al.
Publicado: (2020)

Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer
por: Trarbach, T, et al.
Publicado: (2010)

TRAIL/TRAIL Receptor System and Susceptibility to Multiple Sclerosis
por: López-Gómez, Carlos, et al.
Publicado: (2011)

TRAIL combinations: The new ‘trail’ for cancer therapy (Review)
por: REFAAT, ALAA, et al.
Publicado: (2014)

N-glycosylation of mouse TRAIL-R and human TRAIL-R1 enhances TRAIL-induced death
por: Dufour, Florent, et al.
Publicado: (2017)

Crossed TRAILs
por: Wells, William A.
Publicado: (2002)

The white trail /
por: Dafydd, Fflur
Publicado: (2011)

The information trail
por: Berman, Carol
Publicado: (2016)

John Trail
Publicado: (1889)

Effects of gonadotropin-releasing hormone agonist on human chorionic gonadotropin activity in granulosa cells of immature female rats
por: TUNGMAHASUK, Doungrut, et al.
Publicado: (2017)

Visuomotor Transformation for the Lead Leg Affects Trail Leg Trajectories During Visually Guided Crossing Over a Virtual Obstacle in Humans
por: Hagio, Shota, et al.
Publicado: (2020)

High susceptibility of metastatic cells derived from human prostate and colon cancer cells to TRAIL and sensitization of TRAIL-insensitive primary cells to TRAIL by 4,5-dimethoxy-2-nitrobenzaldehyde
por: Kim, Hak-Bong, et al.
Publicado: (2011)

IL-27 Enhances the Expression of TRAIL and TLR3 in Human Melanomas and Inhibits Their Tumor Growth in Cooperation with a TLR3 Agonist Poly(I:C) Partly in a TRAIL-Dependent Manner
por: Chiba, Yukino, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_nj911ao2vs529iqot624350o65